Monitor shareholder votes and SEC effectiveness. The deal's success hinges on the $150M PIPE closing. If approved, INM stock will effectively represent a small fraction of the combined entity. Traders should consider the massive dilution and potential upside from the PIPE-funded pipeline.
Price Chart
Executive Summary
InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeutics, where Mentari shareholders will receive a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations. Existing INM shareholders face massive dilution but receive contingent value rights. The deal transforms the company but substantially dilutes current holders.
Key Financial Metrics
Key Facts
- Reverse merger: Mentari Therapeutics merges with INM via a two-step process, with Mentari shareholders receiving majority ownership.
- Concurrent PIPE of at least $150 million from investors, including conversion of existing convertible notes.
- INM shareholders receive contingent value rights (CVRs) for future payments.
- Mentari equity value set at $125 million (excluding PIPE proceeds), with INM parent valuation capped at $10 million.
- Net cash adjustment formula for INM potentially reduces its valuation, with a base of negative $3.4 million.
- Deal subject to shareholder approvals, SEC registration, Nasdaq listing, and other conditions.
- Termination fee of $400,000 if INM takes a superior offer, and $4 million if Mentari fails to close.
Financial Impact
PIPE of at least $150 million; post-merger entity valuation implied in hundreds of millions, but existing INM shareholders heavily diluted.
Risk Factors
- Failure to raise minimum PIPE amount ($150M) could kill the deal.
- Regulatory or shareholder approval delays or denials.
- Massive dilution for existing INM shareholders reduces per-share value.
- Integration risks and execution of Mentari's pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001213900-26-058800 |
| Document: ea029148201ex10-5.htm | 0001213900-26-058800 |
| Document: ea029148201ex10-4.htm | 0001213900-26-058800 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 425 | $1.31 $1.39 | ▲ +6.11% | ▲ +6.61% | $1.33 (+1.53%) |
Jul 10, 2026 12w ago | 8-K | $1.57 $1.52 | ▲ +3.18% | ▲ +2.40% | $1.33 (+15.29%) |
Jul 2, 2026 13w ago | S-4 | $1.56 $1.66 | ▼ −6.41% | ▼ −5.48% | $1.33 (+14.74%) |
Jun 11, 2026 16w ago | Insider Cluster | $1.58 $1.49 | ▼ −5.70% | ▼ −6.13% | $1.33 (−15.82%) |
Jun 10, 2026 16w ago | 8-K | $1.51 $1.48 | ▼ −1.99% | ▼ −5.42% | $1.33 (−11.92%) |
May 19, 2026 19w ago | 425 | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.33 (−16.87%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.33 (−16.87%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.66 | ▼ −3.75% | ▼ −1.45% | $1.33 (+16.87%) |
Apr 27, 2026 22w ago | 8-K | $0.7010 $0.7480 | ▼ −6.70% | ▼ −5.01% | $1.33 (−89.73%) |
Apr 3, 2026 26w ago | 8-K | $0.6950 $0.7130 | ▲ +2.59% | ▼ −1.54% | $1.33 (+91.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access